Cart
sales@molnova.com
Cediranib
CAS No. 288383-20-0
Cediranib( AZD2171 | AZD 2171 | AZD-2171 )
Catalog No. M13883 CAS No. 288383-20-0
A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 60 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 54 | In Stock |
|
| 10MG | 80 | In Stock |
|
| 25MG | 131 | In Stock |
|
| 50MG | 174 | In Stock |
|
| 100MG | 248 | In Stock |
|
| 200MG | 453 | In Stock |
|
| 500MG | 727 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCediranib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.
-
DescriptionA highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively; also inhibits c-Kit and PDGFRβ with IC50 of 2 and 5 nM, >36-fold selectivity over PDGFR-α, >1000-fold over Flt-3 and EGFR; inhibits VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM in human umbilical vein endothelial cells; inhibits angiogenesis, neovascular survival and tumor growth in vivo. Ovarian Cancer Phase 3 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsAZD2171 | AZD 2171 | AZD-2171
-
PathwayAngiogenesis
-
TargetVEGFR
-
Recptorc-Kit|PDGFRβ|VEGFR1/FLT1|VEGFR2/KDR|VEGFR3/FLT4
-
Research AreaCancer
-
IndicationOvarian Cancer
Chemical Information
-
CAS Number288383-20-0
-
Formula Weight450.5053
-
Molecular FormulaC25H27FN4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 49 mg/mL
-
SMILESCOC1=C(OCCCN2CCCC2)C=C2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1
-
Chemical NameQuinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400.
2. Denduluri N, et al. Clin Breast Cancer. 2005 Dec;6(5):460-3.
3. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95.
4. Cao C, et al. Cancer Res. 2006 Dec 1;66(23):11409-15.
molnova catalog
related products
-
Lenvatinib
Lenvatinib (E7080) is a multitargeted kinase inhibitor with IC50s of 4/5.2/22/46 nM for VEGFR2/VEGFR3/VEGFR1/FGFR1 in cell free assays.
-
Brivanib alaninate
A prodrug of Brivanib, which is a dual inhibitor of VEGFR2 and FGFR1 with IC50 of 25 nM and 148 nM respectively.
-
AAL-993
AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.
